|
||
|
|
|
||
|
|
The Figure repeats the therapy recommendations from the ACCF/AHA/ESC* Guidelines[91][92] for the management of patients with AFib, but highlights that the current European (ESC) guidelines [93] are slightly more aggressive than the American, in that they recommend for replacing antiplatelet therapy (with aspirin) with anticoagulant therapy most patients with a CHA2DS2-VASc score of 1 or more.
Reiffel JA. Am J Med 2013; 126: 00-00.
[*Abbrevs: ACCF, American College of Cardiology Foundation; AHA, American Heart Association; ESC, European Society of Cardiology]
[91] Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS Focused updates incorporated into fthe ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57:e101-e198.
[92] Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011;57:1330-1337.
[93] Camm AJ, Lip GY, De Caterina R, et al; ESC Committee for Practice Guidelines (CPG),. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747.